Anti-PD-1 antibodies have been widely used in a variety of cancer types, including non-small-cell lung carcinoma, melanoma, colorectal cancer and renal cell carcinoma, and have shown significant antitumor activity over the past decade [29–32]. Here, PDCD1 is linked to melanoma.